Anyway, this trial is going ahead because the Navy and FDA are in talks to make it happen. The Navy and Biopoure are addressing a concern of the FDA by using a preventative drug in conjunction with Hemopure.

Ridgeland, MS, MAY 18, 2009 (EventX/Knobias.com via COMTEX) — By Fain Hughes, fhughes@knobias.com

Biopure Corporation (BPUR) announced that the FDA has advised the U.S. Naval Medical Research Center (NMRC) by letter that it may not initiate a clinical trial of Biopure’s oxygen therapeutic Hemopure(R) under a proposed protocol submitted to the FDA in March 2009. The study, “Restore Effective Survival in Shock” (RESUS) was first proposed and submitted to the FDA in 2005. The proposed trial was placed on clinical hold at that time. It has been resubmitted repeatedly in response to FDA comments and to address comments made by the FDA Blood Products Advisory Committee at an open meeting held in December 2006. Each subsequent submission, including the most recent, was placed on clinical hold.

The company expects the NMRC to seek FDA approval for a clinical trial of Hemopure with a concomitant drug to address vasoactivity, which occurs with the use of Hemopure alone. The NMRC and the FDA are in discussions concerning such a trial, and the NMRC is conducting preclinical studies recommended by the FDA to prepare for such a trial. The NMRC continues to buy Hemopure for this testing.

KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.

FROM YESTERDAY

I will explain more later but right now dump it big time.

UPDATE 1: It has settled down. If you have not sold then hold. This will work itself out. I am preparing an article on what is going on for publication later today. This stock is still going to be a winner. It is just a matter of time.

UPDATE 2: I recommended selling this stock because it was in a free fall after the FDA again rejected the RESUS Clinical Trial that the US Navy wanted to conduct. I took about a $160.00 loss on my sale and the current price is just below where I sold after reaching a low of $0.165 / share.

It did not completely tank, in fact I am a bit surprised by BPUR’s ability to rebound to and maintain its > $0.20/share price.

Technorati Tags: Biopure, BPUR, Hemopure, US Navy, RESUS, RESUS Clinical Trial

Related posts:

1. NIA Founder to appear on Peter Schiff Radio Show – SCAM UPDATE The NIA has been outed again today by Peter Schiff...
2. Burzynski Cures Cancer – The Magic of Antineoplastons THIS VIDEO WILL BE TAKEN DOWN BY THE OWNER ON...

So what is a pump and dump? Well someone or some group somewhere promotes the stock, usually through the Internet, and then sells when all of the suckers buy in high. I just bought 4000 shares for $0.2580 per share. I will hold these in anticipation of some FDA approval for clinical trial news (which I am convinced is a no-brainer) or for the next pump and dump.

USA Only

Canada, UK, Australia

For your information, the pump and dump is easily detectable. For me, if the stock starts rising rapidly and there is no news at Google or Yahoo, then it is a pump and dump. I will sell when I think it is maxed out. With this stock, when I saw the price slide by more than 2 cents from its daily high then I sold. So far I have made over $1000 US Funds.

Just so you know…I do not let a computer monitor my this process. I manually watch it and manually execute the trade. To me it is worth a few hundred or perhaps a thousand dollars to take 3 or 4 hours to monitor the progress of the pump and dump.

To sell or not to sell is the big ‘if’ in this equation. But look at it this way. If you have made 40-60% on your investment why not cash out? If you sell before it does max, don’t fret…you still have made some good returns.

Anyway I am back in and this is round three of owning this stock. Whether I win or lose at this stage does not matter. I am now using my profits to play my little game.

Technorati Tags: pump and dump, stocks, BPUR, penny stock, penny stocks, penny stock experiment

Related posts:

1. NIA Founder to appear on Peter Schiff Radio Show – SCAM UPDATE The NIA has been outed again today by Peter Schiff...
2. The Mad Ape gets scammed by the NIA I like to think that I am a rather intelligent...
3. My sure-fire scheme to make money: Buy Shares in PSLV With the markets under attack by the Banksters for the...

The company name is Biopure Corporation (NASDAQ: BPUR). Back in early April I bought 4000 shares this company after reading that the Federal Drug Administration (FDA) rejected the companies primary product Hemopure from clinical trial.

First about Hemopure. Hemopure is what is considered a blood substitute. It is for use in trauma victims where blood is not readily available or for other reasons, such as religion, blood transfusion is not an option. You will here this product constantly referred to as an oxygen delivery system, but just keep in mind that it replaces human blood.

So why was it rejected? The FDA said that there are safety concerns related to the potential of heart and kidney damage. Fair enough I thought, not a good investment idea…so I was going to pass. That was until I realized that the FDA, with their rejection of Hemopure, had declared war on the US Military.

If there is one thing that I know, it is you don’t piss off the US Military. Upon hearing this news, The US Navy fired off a scathing report, saying that the FDA did not have a clue what they were talking about. In fact the Military accused the FDA of conflict of interest, which does not surprise me. I have never gone on a rant about the FDA, but suffice to say I think it is one of the most corrupted arms of the Federal Government. I will sound off on them at a later date but for now I will stick with Hemopure and why I think it is a can’t miss opportunity.

The military has a great need for this product, especially for battlefield trauma where blood products are not available. Hemopure stores for months at room temperature and is intended for short term use to aid in patient recovery. In other words, soldiers, who would have died on the battlefield due to blood loss, have a chance with this product.

From the Boston Globe:

Navy rips FDA for blocking clinical trial

Report says agency biased on Biopure’s blood substitute

An internal Navy report blasts the Food and Drug Administration for blocking clinical trials of a blood substitute manufactured by Biopure Corp., a struggling biotech company based in Cambridge.

The Navy ultimately hopes to use the experimental product, called Hemopure, to treat military personnel wounded in battle, where traditional blood transfusions aren’t readily available. But for the past four years, the FDA has consistently rejected Biopure and the Navy’s efforts to test the product in clinical trials, citing safety worries and other concerns.

Now the Navy has commissioned a strongly worded report, obtained by the Globe, that concluded the FDA reviews were “faulty.”

“The reviews had consistent patterns of erroneous, misleading, and anecdotal statements, reporting bias, changing requirements, no ‘sense of urgency,’ ” as well as conflicts of interest.

FDA spokeswoman Karen Riley said the agency recognizes the importance of developing products to help both military and civilian trauma patients, but must also make sure the trials do not “involve unreasonable risks to patients. There have been significant safety concerns raised about this class of products,” Riley said, noting some studies linked the products to toxic effects, including heart and kidney damage.

Biopure declined to comment.

A Navy spokesman said it plans to submit an edited version of the report to research journals, but added it is premature to discuss the findings. The report, dated March 13, was written by Captain Daniel Freilich, a program director at the Naval Medical Research Center, along with 13 coauthors, mostly university medical professors.

One of the report’s academic coauthors said he has been frustrated by the FDA’s resistance to allowing the Navy tests to go forward, because so many patients die of massive blood loss on their way to the hospital.

“If we can get a blood substitute, it would make all the difference in the world,” said Joseph Acker, executive director of Birmingham Regional Emergency Medical Services System in Birmingham, Ala. “It would probably save more lives than anything we could do in EMS.”

Still, blood substitutes have been dogged by safety concerns.

Last year, the Journal of the American Medical Association published a study that concluded hemoglobin-based blood substitutes, such as Hemopure, are potentially deadly and should not be tested in humans. Biopure subsequently demanded a retraction and sued the coauthor of the article – a senior investigator with the National Institutes of Health – for libel, saying the study was flawed. Hemopure is manufactured from cow’s blood.

South Africa, the only country to approve Hemopure for human use, decided to revoke its approval last year following the Journal of the American Medical Association study. The company is appealing that decision.

But a coauthor of the Navy report said the safety concerns are moot, because the Navy has proposed testing Hemopure in patients with severe blood loss who would otherwise likely die. Last month, the Navy submitted a revised application to test the drug in trauma patients.

“There is a huge need,” said Lewis Kaplan, associate professor of trauma surgery at the Yale School of Medicine in New Haven, adding he was baffled by the FDA’s resistance.

But Biopure may be running out of time. The company was forced to lay off all but five employees to conserve its dwindling cash.

In February, the company hired Newbury Piret & Co., a Boston investment banking firm, to advise on its strategic options.

Biopure’s stock closed at 17 cents yesterday, giving the company a market value of just $7 million.

The company has also struggled to distance itself from several former executives.

In 2005, the Securities and Exchange Commission sued Biopure and several former executives for misleading investors about Hemopure’s prospects for approval. The parties ultimately settled.

In addition, another former Biopure executive, Howard Richman, pleaded guilty last month to pretending to be gravely ill with colon cancer to avoid a suit from securities regulators. Richman, who left the company in 2003, paid a $150,000 fine last year and faces up to 10 years in prison.

In October 2005, Biopure warned the FDA that the SEC probe presented a possible conflict of interest, because some of the FDA reviewers were also witnesses in the case against the company.

I have already made some significant scratch off of this company. Like I said in the beginning, I bought 4000 shares. What I didn’t tell you was that I sold all of them 2 days later. 2000 at $0.331 and 2000 at $0.313. My initial by in price was $0.178 per share. That is $576.00 profit for two days of investing. Not bad. Not bad at all.

I had sold because everyone was buying in hoping that the FDA would quickly overturn their decision. I knew that the wheels of government turn slowly thus waited a few days for the price to fall back. I then bought in at $0.22799 per share for 5200 shares. The price on this has fluctuated up and down slightly since my second buy and I will continue to hold my position as I basically playing this stock for free.

So if you read the above news story you will see that the military want this product. I live with the belief that when the military wants something bad enough…the military gets it. I believe that the FDA will be pressured into turning their decision around and soon.

Why?

1) The military wants it.

2) Religious groups, such as Jehovah’s Witnesses, accept this product.

3)A lot of doctors are staking their reputations and careers on this company and product. In fact you will see some video clips links below from medical professionals involved in recent administering of this product. I don’t know what these experimental treatments mean with respect to the FDA denying clinical trials but the product is being used right now.

The medical professional explain in great detail all of the benefits of this product. This is can’t miss and a carries the Mad Ape Seal of Approval – whatever in the hell that means?

Mad Ape Recommended On-line Trading Platforms

USA Only

Canada, UK, Australia

http://hfrp.umm.edu/cucases/part1.html
Welcome: Colin Mackenzie, M.D., Professor of Anesthesiology, Associate
Professor Physiology, University of Maryland School of Medicine:
Moderator
Extreme and Total Support in Autoimmune Hemolytic Anemia: Gary
Thompson, M.D., Medical Director, Saint Luke’s Blood Management
Program, Saint Luke’s Hospital, Kansas City

http://hfrp.umm.edu/cucases/part2.html
Compassionate Use HBOC-201 for Unexpected Surgical Bleeding when Blood
was not an Option: Patricia Ford, M.D., Medical Director of Bloodless
Medicine and Stem Cell Transplant Programs, Pennsylvania Hospital,
Clinical Associate Professor of Medicine, University of Pennsylvania:
10 min

http://hfrp.umm.edu/cucases/part3.html
Update on Clinical Use HBOC-201 in South Africa: Lewis Levien,
M.D.PhD, Specialist Surgeon, Life Fourways Hospital, Johannesburg: 10
min

http://hfrp.umm.edu/cucases/part4.html
A Bridge to Blood: Paul Marik, M.D., Professor of Medicine, Director
of Pulmonary and Critical Care, Thomas Jefferson University
Philadelphia: 10 min

http://hfrp.umm.edu/cucases/part5.html
Management of Acute Symptomatic Anemia with HBOC-201 in a Jehovah’s
Witness Patient with Acute Lymphocytic Leukemia: Laura L. Donahue,
M.D. Attending Physician Monter Cancer Center North Shore-Long Island
Jewish Health System, Instructor, Clinical Medicine, NYU School of
Medicine: 10 min

http://hfrp.umm.edu/cucases/part6.html
Cerebral and Mixed Venous Perfusion Markers in a Trauma patient during
HBOC-201 Infusion: Jonathan Marinaro, M.D., Assistant Professor of
Surgery and Emergency Medicine, University of New Mexico, Albuquerque:
10 min

http://hfrp.umm.edu/cucases/part7.html
The Compassionate Use HBOC-201 Physician Facilitator: Gerson
Greenburg, M.D., Emeritus Professor of Surgery, Brown University, Vice
President Medical Affairs, Biopure Corporation, Cambridge, MA: 10 min

http://hfrp.umm.edu/cucases/part8.html
Temporizing support for a Jehovah’s Witness Patient after Kidney
Transplant: Hamid Rabb, M.D., Professor of Medicine, Physician
Director, Kidney Transplantation, Johns Hopkins University School of
Medicine: 10 min

http://hfrp.umm.edu/cucases/part9.html
PANEL Gary Thompson, M.D; Patricia Ford, M.D.; Lewis Levien, M.D.;
Paul Marik, M.D.; Laura Donahue, M.D.; Jonathan Marinaro, M.D.; Gerson
Greenburg, M.D.; Hamid Rabb, M.D.; Aryeh Shander, M.D.: 25 min

Disclaimer: I am not a professional investment adviser. This blog posting is for information purposes only. Investing is not an accurate science and you pays your money and you takes your chances. Do not come bitching to me if the price heads south.

Technorati Tags: Hemopure, Biopure, BPUR, Penny Stocks, US Military, FDA, US Navy, Penny Stock Experiment

Related posts:

1. ‘Preppers’ stock up on guns’n'gear as financial doom looms So the government says that these type of people are...
2. The Modern Day Pearl Harbor (US Dollar Crisis, Stock Market Crash 2011 & False Flag Imminent) The Modern Day Pearl Harbor (US Dollar Crisis, Stock Market...

Dear Trader, Change is in the air. We recently elected a new president that promises change. The world economy is in flux, and the market regularly takes us for a ride. Recently, there have been some changes among online brokers. One has changed the game (again) for their “free trade” deal. Another has been bought by still a third. There’s another big change we need to talk about. A lot of folks out there are looking to CHANGE to a new broker. To help make the move painless, TradeKing is offering to reimburse new clients for up to $150 in account transfer fees. So now there’s no risk to try the discount broker that was ranked #1 two years in a row by SmartMoney Magazine (2006 & 2007). There have been some changes at TradeKing, too. On February 13, 2009 we launched our new, improved homepage and navigation. Our Trader’s Network is stronger than ever, and we’re always improving our service and platform that been recognized as tops in the business by Kiplinger, Smart Money Magazine, and Barron’s. Best Regards, TradeKing

Technorati Tags: TradeKing.com, TradeKing, TradeKing Pays Transfer Fees, online brokerage accounts, online trading accounts

Related posts:

1. The Greatest Wealth Transfer in History : James Anderson, GoldSilver.com A two-part interview with James Anderson, the Managing Director of...

According to SmartMoney.com

One firm managed to earn five stars for best overall service: TradeKing. The company recently opened a new client-service center, and the effort seems to be paying off: Live chat worked without a hitch, our e-mails got answered in a speedy average of five minutes, and a phone rep even called us back to clarify his response to one of our questions. Now, that’s service.

Service is where it is at. So being a Canadian, I can’t use them. If you have anything to say about TradeKing.com – good or bad…please leave a comment here.

To register for a TradeKing account click here now

Technorati Tags: TradeKing, TradeKing.com, Questrade, Questrade.com, online brokers, online stocks

Related posts:

1. My sure-fire scheme to make money: Buy Shares in PSLV With the markets under attack by the Banksters for the...
2. Are you a Fiatard? Gold is not in a bubble. Only a retard says that Gold is in a bubble....
3. The Silver Fraud Bubble Will Burst The only bubble in silver is silver fraud and flagrant...

I am jumping the gun here by releasing this ahead of my planned release date but feel it is now necessary to let my readers know who I use for my on-line brokerage account. My readers have forced me to jump the gun because of their questions.

I am currently trying to work out a deal with a reputable US-based online brokerage but thus far we have not completed our negotiations. Because of the holiday season people are on vacation so I am in wait mode. For now I recommend that you use TradeKing. While they may not be the cheapest their costs are low and they have an excellent reputation.

I Love to Expose Myself

And no I am not a perv. I am just grabbing your attention in an evil shifty marketing sort of way. I don’t mind exposing my affiliate id because it has to be used to get the $50.00 in free trades that they will give you when you sign up through me.

The Perils of Due Diligence

Keep in mind that an online brokerage is a bit of a pain in the butt to sign up with. They have to do a lot of due diligence to verify who you are, where you live, and make sure that you are not a front for some sort of money laundering scheme.

I was able to complete all of my documentation online. It took me about 1 hour. They have a very good process but beware you will have to reveal a lot of personal identification. Your Social Insurance number is mandatory, as well as they will be using information in your credit report to verify that you are you. They also have a method whereby you create an e-signature for signing your documents.

All of your information provided is available to government agencies so if you are thinking that you will be dodging taxes illegally, think again. As for legal tax dodging, that is country specific and I am not an accountant. You should probably get one.

Once you have been verified you will be then asked to fund your account. If you are trading stocks, such as I am, then you will need to fund your account with a $1,000.00 CDN minimum. I funded my account via my online banks bill paying system. Questrade is a legal vendor from my banks perspective.

Once the transfer has been done you will wait approximately 5 – 7 days for your user account and password to be sent to you. These will not be the same ones that you registered with. Your trading account is separate from you Questrade account.

Penson

Somewhere along the way you will be prompted to register for penson services. It is a free service that will supply a record of all of your transactions sent to your email address as a pdf file. I forget (sorry) where I was prompted to sign up for that, but I recommend that you do the same. If someone can report back to me where they were prompted to join this, it would be appreciated.

Now why do I choose Questrade? It is A-B-C easy.

AFFORDABILITY

Questrade charge 1 cent per share for each trade to a maximum cost of $9.95, with a minimum cost of $4.95.

BETTER PRODUCTS

Whether it is to trade stocks or options, dabble in forex, trade gold, or mutual funds…Questrade offers you a 1-stop shop for all of your financial needs. They also have RSP’s and Tax-Free accounts for Canadians.

CUSTOMER SERVICE

Questrade has the best customer service that I have ever seen. Phone support, email support, online live help desk, and an extensive FAQ. I have personally tested all levels of support and have been extremely happy. In fact that is why I did not publish who I was dealing with until now. I wanted to make sure that their interface worked and that they were reputable. It did and they are.

Sign up for Questrade by clicking here.

Technorati Tags: Questrade, Questrade Affiliate Program, TradeKing, TradeKing.com, Questrade.com, penson

Related posts:

1. My sure-fire scheme to make money: Buy Shares in PSLV With the markets under attack by the Banksters for the...
2. Are you a Fiatard? Gold is not in a bubble. Only a retard says that Gold is in a bubble....
3. Tim TJ Wass: 16 FACTS THAT PROVE RON PAUL IS BEST CHOICE FOR PRESIDENT Tonight I read an online article about how an Iowa...